500.02 Clinical Outcomes At 2 Years of The Absorb Bioresorbable Vascular Scaffold Versus The Xience Drug-eluting Metallic Stent In Patients Presenting With Acute Coronary Syndrome Versus Stable Coronary Disease - Aida Trial Sub-study.

Ruben Tijssen,René J. van der Schaaf,Robin P. Kraak,Maarten A. Vink,Sjoerd H. Hofma,Karin Arkenbout,Auke Weevers,Laura S.M. Kerkmeijer,Patrick W. Serruys,Yoshinobu Onuma,Marcel A. Beijk,Karel T. Koch,Jan Baan,Marije M. Vis,Jan J. Piek,Jan G.P. Tijssen,José P.S. Henriques,Robbert J. de Winter,Joanna J. Wykrzykowska

500.02 Clinical Outcomes At 2 Years of The Absorb Bioresorbable Vascular Scaffold Versus The Xience Drug-eluting Metallic Stent In Patients Presenting With Acute Coronary Syndrome Versus Stable Coronary Disease - Aida Trial Sub-study.

2019

Ruben Tijssen
René J. van der Schaaf
Robin P. Kraak
Maarten A. Vink
Sjoerd H. Hofma
Karin Arkenbout
Auke Weevers
Laura S.M. Kerkmeijer
Patrick W. Serruys
Yoshinobu Onuma
Marcel A. Beijk
Karel T. Koch
Jan Baan
Marije M. Vis
Jan J. Piek
Jan G.P. Tijssen
José P.S. Henriques
Robbert J. de Winter
Joanna J. Wykrzykowska

Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI) might lead to better outcomes when compared to conventional treatment with metallic drug-eluting stents. ACS patients (STE-ACS

Keywords:

Cardiology
Internal medicine
Drug
Disease
Stent
Scaffold
Acute coronary syndrome
Medicine
bioresorbable vascular scaffold
Percutaneous coronary intervention
in patient
coronary disease
Conventional PCI

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations